Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Medartis Holding AG ( (CH:MED) ) just unveiled an update.
Medartis Holding AG reported a core sales growth of 11.7% in 2024, driven by strong performance in the EMEA and USA markets, and improved its core EBITDA margin to 19.0%. The company is strategically expanding its market presence with the acquisition of a majority stake in NeoOrtho in Brazil and preparing for the full acquisition of Keri Medical after FDA approval of the TOUCH prosthesis. Looking ahead, Medartis expects further growth in 2025, with a focus on innovative solutions and customer orientation to unlock additional growth opportunities.
More about Medartis Holding AG
Medartis Holding AG is a leading orthopedic company specializing in head and extremity surgery. It is known for its comprehensive portfolio and precision quality, focusing on providing complete solutions to its customers. The company operates primarily in the EMEA region, the USA, and other international markets, offering innovative solutions and expanded digital offerings in the orthopedic industry.
YTD Price Performance: 24.56%
Average Trading Volume: 3,641
Current Market Cap: CHF951.7M
See more insights into MED stock on TipRanks’ Stock Analysis page.